

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2257)

VOLUNTARY ANNOUNCEMENT

SIRNAOMICS APPOINTS DR. FRANCOIS LEBEL AS SENIOR VICE PRESIDENT FOR PRECLINICAL AND CLINICAL DEVELOPMENT

The board (the “**Board**”) of directors (the “**Directors**”) of Sirnaomics Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**” or “**Sirnaomics**”) hereby informs the shareholders and potential investors of the Company of the attached press release that Dr. Francois Lebel, M.D., an experienced biopharmaceutical industry executive, has been appointed as Senior Vice President for preclinical and clinical development of the Group.

This announcement is made by the Company on a voluntary basis. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sirnaomics Ltd.

Yang (Patrick) Lu

Chairman and Executive Director

Hong Kong, July 28, 2023

As at the date of this announcement, the Board comprises Dr. Yang Lu (alias Patrick Lu), Dr. Michael V. Molyneaux, Dr. David Mark Evans and Dr. Xiaochang Dai as executive Directors, Mr. Mincong Huang and Mr. Jiankang Zhang as non-executive Directors, and Dr. Cheung Hoi Yu, Mr. Fengmao Hua, Ms. Monin Ung and Ms. Shing Mo Han, Yvonne (alias Mrs. Yvonne Law) as independent non-executive Directors.

Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development

Hong Kong SAR | Germantown, MD, USA | Suzhou Biobay, China, July 28, 2023 — Sirnaomics Ltd. (the “**Company**”, Stock Code: 2257.HK, together with its subsidiaries, the “**Group**” or “**Sirnaomics**”), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that Dr. Francois Lebel, M.D., an experienced biopharmaceutical industry executive, has been appointed as Senior Vice President for preclinical and clinical development of the Group.

“With multiple drug candidates moving into clinical studies, including two clinical trials advancing to late-stage development, Sirnaomics is embarking on a journey to push its innovative drug candidates past the finish line, which requires a seasoned leader with a successful track record,” said Dr. Patrick Lu, Founder, Chairman of the Board, Executive Director, President and Chief Executive Officer of Sirnaomics. “With Dr. Lebel’s in-depth knowledge and experience in novel drug product marketing approvals, Dr. Lebel’s addition to Sirnaomics’ senior leadership will greatly enhance our capability to advance its therapeutic candidates through the late-stage product development.

Dr. Lebel is a strategic leader with broad drug development experience including immuno-oncology and nucleic acid therapeutics. Throughout his 30-year biopharma career at companies such as GSK, Pfizer, Baxter Healthcare, MedImmune, and Chiron Corporation, Dr. Lebel has designed and managed international research and development programs to successfully achieve multiple product marketing approvals. His recent senior leadership roles include Executive Vice President for Research & Development and Chief Medical Officer at Spectrum Pharmaceuticals (a Nasdaq listed company; stock code: SPPI), where he was responsible for preclinical and clinical development, regulatory affairs and pharmacovigilance/drug safety, and successfully secured a novel drug marketing authorization at the U.S. Food and Drug Administration (FDA) in 2022. After joining Sirnaomics as Senior Vice President for preclinical and clinical development, Dr. Lebel will take a leading role in the Group’s late-stage product development of the innovative RNAi drug candidates.

Dr. Lebel indicates, “I am delighted to join the Sirnaomics team at this pivotal time for STP705 with the recent positive data in skin cancer and the Group’s evolving diversified pipeline. I look forward to working closely with the U.S. FDA and investigators to efficiently generate the required data to support a marketing application.”

About Sirnaomics

Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies: Polypeptide Nanoparticle Formulation and the 2nd generation of GalNAc conjugation, the Group has established an enriched drug candidate pipeline. Sirnaomics is currently holding a leadership position on advancing RNAi therapeutics for oncology application with multiple successes of its clinical programs for STP705 and STP707. STP122G represents the first drug candidate of GalAhead™ technology entering clinical development. With the establishment of the Group's manufacturing facility, Sirnaomics currently is undergoing a transition from a biotech company to a biopharma corporation. Learn more at: www.sirnaomics.com.

CONTACT:

Investor Relations:

Nigel Yip, MBA
Chief Financial Officer, Sirnaomics
Email: NigelYip@sirnaomics.com

U.S. Media Contact:

Alexis Feinberg
Tel: +1 203 939 2225
Email: Alexis.Feinberg@westwicke.com

Asia Media Contact:

Heidi So
Tel: +852 2864 4826
Email: sprg_sirnaomics@sprg.com.hk